Skip to main content
CADL
NASDAQ Life Sciences

Candel's CAN-2409 Phase 3 Prostate Cancer Trial Shows 39% DFS Improvement in Extended Follow-up

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$9.018
Mkt Cap
$642.376M
52W Low
$4.35
52W High
$9.27
52W Position info
107% above low
Off High info
2.7% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

CADL has more than doubled off its 52-week low of $4.35 on elevated volume (2.0× avg).

Summary

Candel Therapeutics announced highly positive extended follow-up data from its pivotal Phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer. Presented at the AUA 2026 Annual Meeting, the data demonstrated a statistically significant and clinically meaningful 39% improvement in prostate cancer-specific disease-free survival (PCa-specific DFS) compared to placebo, after a median follow-up of 58 months. Consistent favorable trends were also observed across multiple secondary and exploratory endpoints, including time to biochemical failure and time to metastasis. This significant de-risking event for a late-stage asset is a major value driver for the clinical-stage biotech, following recent Q1 2026 financial results that showed a strong cash position. The positive data could lead to substantial investor confidence and a re-rating of the stock, with future catalysts including regulatory discussions and further data maturation.

At the time of this announcement, CADL was trading at $9.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $642.4M. The 52-week trading range was $4.35 to $9.27. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CADL - Latest Insights

CADL
Nov 13, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $5.03 info
Change: -$0.0853 (-2%) info
Market Cap: $393.406M info
CADL
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $5.03 info
Change: -$3.37 (-40%) info
Market Cap: $393.406M info
CADL
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $5.03 info
Change: -$3.37 (-40%) info
Market Cap: $393.406M info
CADL
Oct 01, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.40
Real-time Price: $5.03 info
Change: -$5.38 (-52%) info
Market Cap: $393.406M info
CADL
Sep 30, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.96
Real-time Price: $5.03 info
Change: -$5.94 (-54%) info
Market Cap: $393.406M info